Pilot Study of Vitamin D Screening Use in Peripheral Arterial Disease Patient Over Maximum Distance Walking
Status:
Completed
Trial end date:
2020-09-21
Target enrollment:
Participant gender:
Summary
The prevalence of peripheral arterial disease (PAD) is greater than 15%. PAD is associated
with an increased risk of cardiovascular death, coronary heart disease and stroke, with a
mortality rate of 5% per year.
Most clinical evidence supports the idea that having normal vitamin D reduces cardiovascular
risk. The data suggests that normalizing vitamin D levels would have a significant impact on
public health, reduce costs and help control the incidence and prevalence of cardiovascular
disease.
There is also a plausible physiological theory, supported by numerous observational studies,
that vitamin D supplementation should be effective in improving cardiovascular outcomes, such
as blood pressure, arterial stiffness, atherosclerosis, endothelial function, and clinical
events.
The investigators hypothesize that routine screening for vitamin D deficiency and
supplementation in case of hypovitaminosis D is effective for improving the maximum walking
distance after 12 weeks of treatment in stage 2 PAD patients .
Phase:
Phase 4
Details
Lead Sponsor:
University Hospital, Angers
Treatments:
Cholecalciferol Ergocalciferols Vitamin D Vitamins